CN114736212A - A kind of furo[3,2-b]indole derivative and its synthesis method and application - Google Patents
A kind of furo[3,2-b]indole derivative and its synthesis method and application Download PDFInfo
- Publication number
- CN114736212A CN114736212A CN202210469120.0A CN202210469120A CN114736212A CN 114736212 A CN114736212 A CN 114736212A CN 202210469120 A CN202210469120 A CN 202210469120A CN 114736212 A CN114736212 A CN 114736212A
- Authority
- CN
- China
- Prior art keywords
- furo
- indole derivative
- formula
- indole
- synthesizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
技术领域technical field
本发明属于有机化合物合成领域,具体涉及一种呋喃并[3,2-b]吲哚衍生物及其合成方法和应用The invention belongs to the field of organic compound synthesis, in particular to a furano[3,2-b]indole derivative, a synthesis method and application thereof
背景技术Background technique
呋喃并[3,2-b]吲哚骨架大量存在于具有生理活性的天然产物或药物分子中,呈现出不同的药物活性,譬如,具有抗过敏性、抗肿瘤活性、镇痛消炎的作用。因此,发展该类化合物合成方法研究,对于含呋喃并[3,2-b]吲哚骨架药物分子的合成具有重要的促进作用。另外,呋喃并[3,2-b]吲哚类衍生物还可以作为重要的有机合成单元,可在过渡金属催化下发生一系列的化学转化反应,构建吲哚啉-3-酮螺环、吲哚并杂环、吲哚-3-酮-2-烯等骨架分子。Furano[3,2-b]indole skeletons are abundantly present in natural products or drug molecules with physiological activity, showing different drug activities, such as antiallergic, antitumor activity, analgesic and anti-inflammatory effects. Therefore, the development of synthetic methods for these compounds has an important role in promoting the synthesis of furo[3,2-b]indole skeleton-containing drug molecules. In addition, furo[3,2-b]indole derivatives can also be used as important organic synthesis units, which can undergo a series of chemical transformation reactions under the catalysis of transition metals to construct indolin-3-one spiro rings, Indolo-heterocycle, indol-3-one-2-ene and other backbone molecules.
目前已知的合成该类骨架的方法还比较少,主要包括:(1)通过多步合成手段合成邻呋喃芳基叠氮化合物,在高温条件下分子内环化得到目标产物;(2)以邻呋喃硝基苯为原料,在烷氧基磷催化下分子内环化,得到呋喃并吲哚骨架;(3)通过多步合成手段构建邻(3-溴-2-呋喃基)芳胺为原料,通过分子内C-NUllmann偶联环化得到目标产物。但上述已报道的合成方法涉及的原料需要多步合成且收率不高,部分原料例如芳香叠氮化合物在实际操作过程中具有一定的危险性,很多反应条件较为苛刻反应温度高达160℃,目标产物收率不高,反应成本较高等缺点。因此,发展更加经济高效、操作简便的呋喃并[3,2-b]吲哚类衍生物的合成方法显得极为重要。Currently known methods for synthesizing such skeletons are relatively few, mainly including: (1) synthesizing o-furan aryl azide compounds by multi-step synthesis, and obtaining the target product by intramolecular cyclization under high temperature conditions; (2) using The o-furanyl nitrobenzene is used as the raw material, and the intramolecular cyclization is carried out under the catalysis of alkoxy phosphorous to obtain the furanoindole skeleton; (3) the o-(3-bromo-2-furyl) arylamine is constructed by a multi-step synthesis method as The starting material is cyclized by intramolecular C-NUllmann coupling to obtain the target product. But the raw materials involved in the above-mentioned reported synthetic methods need multi-step synthesis and the yield is not high, some raw materials such as aromatic azides have certain dangers in the actual operation process, and many reaction conditions are relatively harsh. The reaction temperature is up to 160 ° C, the target The product yield is not high, and the reaction cost is relatively high. Therefore, it is extremely important to develop more cost-effective and easy-to-operate synthetic methods for furo[3,2-b]indole derivatives.
发明内容SUMMARY OF THE INVENTION
本发明的目的是提供一种呋喃并[3,2-b]吲哚衍生物及其合成方法和应用,提供了一种原料简单易得、反应条件温和的合成方法。The purpose of the present invention is to provide a furano[3,2-b]indole derivative, a synthesis method and application thereof, and a synthesis method with simple and easily available raw materials and mild reaction conditions.
本发明提供了一种呋喃并[3,2-b]吲哚衍生物,其结构如式(I)所示:The present invention provides a furo[3,2-b]indole derivative, the structure of which is shown in formula (I):
式(I)中,In formula (I),
R为氢、C1-C20烷基或卤素。R is hydrogen, C1-C20 alkyl or halogen.
本发明还提供一种呋喃并[3,2-b]吲哚衍生物的合成方法,具体步骤为:以对甲苯磺酰基保护的2-(2-呋喃基)芳胺化合物为原料,在保护气氛下,加入有机溶剂、催化剂、氧化剂和碱,催化合成得到如式(I)所示的呋喃并[3,2-b]吲哚衍生物;The present invention also provides a method for synthesizing furo[3,2-b]indole derivatives. The specific steps are as follows: using a p-toluenesulfonyl-protected 2-(2-furanyl)arylamine compound as a raw material; Under the atmosphere, adding an organic solvent, a catalyst, an oxidizing agent and a base, the furo[3,2-b]indole derivative represented by the formula (I) is obtained by catalytic synthesis;
其反应过程如式(II)所示:Its reaction process is shown in formula (II):
式(II)中,R为氢、C1-C20烷基或卤素;所述催化剂为钯催化剂。In formula (II), R is hydrogen, C1-C20 alkyl or halogen; the catalyst is a palladium catalyst.
优选地,所述对甲苯磺酰基保护的2-(2-呋喃基)芳胺化合物:催化剂:氧化剂:碱的摩尔比为1:(0.1-0.5):(1-2):(0.5-2)。Preferably, the molar ratio of the p-toluenesulfonyl-protected 2-(2-furyl) arylamine compound: catalyst: oxidant: base is 1: (0.1-0.5): (1-2): (0.5-2 ).
优选地,所述对甲苯磺酰基保护的2-(2-呋喃基)芳胺化合物:催化剂:氧化剂:碱的摩尔比为1:0.1:2:0.5。Preferably, the molar ratio of the p-toluenesulfonyl-protected 2-(2-furyl) arylamine compound: catalyst: oxidant: base is 1:0.1:2:0.5.
优选地,所述钯催化剂选自PdCl2、Pd(TFA)2、Pd(OAc)2、PdCl2(PPh3)2、Pd(PPh3)4、Pd(dba)2和Pd2(dba)3中的一种或多种。Preferably, the palladium catalyst is selected from the group consisting of PdCl 2 , Pd(TFA) 2 , Pd(OAc) 2 , PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , Pd(dba) 2 and Pd 2 (dba) one or more of 3 .
优选地,所述钯催化剂为PdCl2。Preferably, the palladium catalyst is PdCl 2 .
优选地,所述氧化剂选自Cu(OAc)2、CuSO4、Cu(acac)2、六氟磷酸四乙氰铜、Cu(OTf)2、AgOAc和Ag2CO3中的一种或多种。Preferably, the oxidant is selected from one or more of Cu(OAc) 2 , CuSO 4 , Cu(acac) 2 , tetraethyl cyanide hexafluorophosphate, Cu(OTf) 2 , AgOAc and Ag 2 CO 3 .
优选地,所述氧化剂为Cu(OAc)2。Preferably, the oxidant is Cu(OAc) 2 .
优选地,所述碱选自Cs2CO3、KOtBu、K2CO3、KOH、NEt3、DBU和K3PO4中的一种或多种。Preferably, the base is selected from one or more of Cs 2 CO 3 , KO t Bu, K 2 CO 3 , KOH, NEt 3 , DBU and K 3 PO 4 .
优选地,所述碱为Cs2CO3。Preferably, the base is Cs 2 CO 3 .
优选地,所述有机溶剂选自1,2-二氯乙烷、乙腈、甲苯、1,4-二氧六环、二甲亚砜、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺和四氢呋喃中的一种。Preferably, the organic solvent is selected from 1,2-dichloroethane, acetonitrile, toluene, 1,4-dioxane, dimethyl sulfoxide, N,N-dimethylformamide, N,N- One of dimethylacetamide and tetrahydrofuran.
优选地,所述反应的温度为50-120℃。Preferably, the temperature of the reaction is 50-120°C.
优选地,所述反应的时间为10-50h。Preferably, the reaction time is 10-50h.
本发明还提供了一种呋喃并[3,2-b]吲哚衍生物在制备抗过敏、抗肿瘤、镇痛消炎药物中的应用。The invention also provides the application of a furo[3,2-b]indole derivative in the preparation of anti-allergic, anti-tumor, analgesic and anti-inflammatory drugs.
在一个具体实施方案中,本发明制备方法中,在氮气下,以对甲苯磺酰基保护的2-(2-呋喃基)芳胺化合物为原料,在保护气氛下,以N,N-二甲基乙酰胺为有机溶剂,以PdCl2为催化剂,以Cu(OAc)2为氧化剂,以Cs2CO3为碱,在80℃下合成得到式(I)所示的呋喃并[3,2-b]吲哚衍生物,如以下反应式(III)所示:In a specific embodiment, in the preparation method of the present invention, under nitrogen, a p-toluenesulfonyl-protected 2-(2-furyl) arylamine compound is used as a raw material, and under a protective atmosphere, N,N-dimethyl acetamide as the organic solvent, PdCl 2 as the catalyst, Cu(OAc) 2 as the oxidant, and Cs 2 CO 3 as the base, at 80 °C, the furo[3,2- b] an indole derivative, as shown in the following reaction formula (III):
其中,R为氢、C1-C20烷基或卤素。Wherein, R is hydrogen, C1-C20 alkyl or halogen.
其中,所述对甲苯磺酰基保护的2-(2-呋喃基)芳胺化合物:PdCl2:Cu(OAc)2:Cs2CO3的摩尔比为1:0.1:2:0.5。Wherein, the molar ratio of the p-toluenesulfonyl-protected 2-(2-furyl) arylamine compound: PdCl 2 : Cu(OAc) 2 : Cs 2 CO 3 is 1:0.1:2:0.5.
其中,所述反应的时间为24-40h。Wherein, the time of the reaction is 24-40h.
本发明的有益效果是:本发明的一种呋喃并[3,2-b]吲哚衍生物的合成方法在钯催化剂的作用下实现NH与呋喃环3位的氢发生偶联环化,得到目标产物。反应条件温和且原料简单易得,具有普适性好、原子经济性高,后处理简单、收率良好(60%-80%),对环境友好等优点。本发明制备方法合成的呋喃并[3,2-b]吲哚衍生物中的呋喃并[3,2-b]吲哚骨架,是许多天然产物和药物分子中的重要结构单元,且大多具有较强的生物活性,能够进一步发生后续化学转化反应,在药物合成方面具有重大研究价值。The beneficial effects of the present invention are as follows: the method for synthesizing a furano[3,2-b]indole derivative of the present invention realizes the coupling cyclization of NH and the hydrogen at the 3-position of the furan ring under the action of a palladium catalyst to obtain target product. The reaction conditions are mild, the raw materials are simple and easy to obtain, and it has the advantages of good universality, high atom economy, simple post-processing, good yield (60%-80%), and environmental friendliness. The furo[3,2-b]indole skeleton in the furo[3,2-b]indole derivatives synthesized by the preparation method of the present invention is an important structural unit in many natural products and drug molecules, and most of them have It has strong biological activity and can further undergo subsequent chemical transformation reactions, and has great research value in drug synthesis.
具体实施方式Detailed ways
为了使本发明所解决的技术问题、技术方案及有益效果更加清楚明白,以下结合实施例,对本发明进行进一步的详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。在不背离发明构思的精神和范围下,本领域技术人员能够想到的变化和优点都被包括在本发明中,并且以所附的权利要求书为保护范围。实施本发明的过程、条件、试剂、实验方法等,除以下专门提及的内容之外,均为本领域的普遍知识和公知常识,本发明没有特别限制内容。In order to make the technical problems, technical solutions and beneficial effects solved by the present invention clearer, the present invention will be further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, but not to limit the present invention. Variations and advantages that can occur to those skilled in the art without departing from the spirit and scope of the inventive concept are included in the present invention, and the appended claims are the scope of protection. The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common knowledge in the field, and the present invention has no special limited contents.
实施例1:4-Ts呋喃并[3,2-b]吲哚化合物(IA)合成Example 1: Synthesis of 4-Ts furo[3,2-b]indole compound (IA)
在氮气氛围下,向反应管中,加入Ts(对甲苯磺酰基)保护的邻呋喃芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(IA),黄色固体,分离收率75%。MP 128-131℃。Under a nitrogen atmosphere, 0.3 mmol of Ts (p-toluenesulfonyl) protected o-furan arylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, and anhydrous copper acetate were added to the reaction tube. 0.6 mmol, 0.15 mmol of cesium carbonate. The reaction was carried out at 80° C. for 24 hours, and after TLC detection was completed, the reaction was cooled to room temperature to obtain the target product of formula (IA), a yellow solid, and the isolated yield was 75%. MP 128-131°C.
产物核磁数据:1H NMR(CDCl3,500MHz):δ2.27(s,3H),7.01(s,1H),7.12(d,J=5.0Hz,2H),7.26-7.28(m,2H),7.53-7.56(m,2H),7.67(d,J=5.0Hz,2H),8.12-8.14(m,1H)。13C NMR(CDCl3,125MHz):δ21.46,102.50,115.34,116.68,118.83,124.02,126.67,129.65,130.23,134.35,139.15,144.44,144.93,146.42。Product NMR data: 1 H NMR (CDCl 3 , 500MHz): δ 2.27(s, 3H), 7.01(s, 1H), 7.12(d, J=5.0Hz, 2H), 7.26-7.28(m, 2H) , 7.53-7.56 (m, 2H), 7.67 (d, J=5.0Hz, 2H), 8.12-8.14 (m, 1H). 13 C NMR (CDCl 3 , 125MHz): δ 21.46, 102.50, 115.34, 116.68, 118.83, 124.02, 126.67, 129.65, 130.23, 134.35, 139.15, 144.44, 144.93, 146.42.
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C17H14NO3S[M+H]+calc.:312.0694;found:312.0698。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C17H14NO3S [ M +H] + calc.: 312.0694 ; found: 312.0698.
实施例2:6-氯-4-Ts呋喃并[3,2-b]吲哚化合物(IB)合成Example 2: Synthesis of 6-chloro-4-Ts furo[3,2-b]indole compound (IB)
在氮气氛围下,向反应管中,加入Ts保护的2-呋喃-5-氯芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(IB),棕色固体,分离收率70%。MP 114-116℃。Under a nitrogen atmosphere, 0.3 mmol of Ts-protected 2-furan-5-chloroarylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, and 0.6 mL of anhydrous copper acetate were added to the reaction tube. mmol, cesium carbonate 0.15mmol. The reaction was carried out at 80° C. for 24 hours, and after TLC detection was completed, the reaction was cooled to room temperature to obtain the target product of formula (IB) as a brown solid with an isolation yield of 70%. MP 114-116°C.
产物核磁数据:1H NMR(CDCl3,500MHz):δ2.31(s,3H),7.00(d,J=2.0Hz,1H),7.17(d,J=8.5Hz,2H),7.25(dd,J=8.5,2.0Hz,1H),7.47(d,J=8.5Hz,1H),7.54(d,J=2.0Hz,1H),7.69-7.71(m,2H),8.15(d,J=2.0Hz,1H)。13C NMR(CDCl3,125MHz):δ21.54,102.47,115.54,117.23,117.29,124.56,126.71,129.83,129.87,130.76,134.20,139.31,143.64,145.31,146.81。Product NMR data: 1 H NMR (CDCl 3 , 500MHz): δ 2.31 (s, 3H), 7.00 (d, J=2.0 Hz, 1H), 7.17 (d, J=8.5 Hz, 2H), 7.25 (dd ,J=8.5,2.0Hz,1H),7.47(d,J=8.5Hz,1H),7.54(d,J=2.0Hz,1H),7.69-7.71(m,2H),8.15(d,J= 2.0Hz, 1H). 13 C NMR (CDCl 3 , 125MHz): δ 21.54, 102.47, 115.54, 117.23, 117.29, 124.56, 126.71, 129.83, 129.87, 130.76, 134.20, 139.31, 143.64, 145.31, 146.81.
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C17H13ClNO3S[M+H]+calc.:346.0305;found:346.0310。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C17H13ClNO3S [ M +H]+calc.: 346.0305 ; found: 346.0310.
实施例3:6-甲基-4-Ts呋喃并[3,2-b]吲哚化合物(IC)合成Example 3: Synthesis of 6-methyl-4-Ts furo[3,2-b]indole compound (IC)
在氮气氛围下,向反应管中,加入Ts保护的5-甲基-2-呋喃芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(IC),黄色固体,分离收率72%。MP 135-136℃。Under nitrogen atmosphere, into the reaction tube, add 0.3 mmol of Ts-protected 5-methyl-2-furanarylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, and anhydrous copper acetate 0.6 mmol, 0.15 mmol of cesium carbonate. The reaction was carried out at 80° C. for 24 hours, and after TLC detection was completed, the reaction was cooled to room temperature to obtain the target product of formula (IC) as a yellow solid, and the isolated yield was 72%. MP 135-136°C.
产物核磁数据:1H NMR(CDCl3,500MHz):δ2.27(s,3H),2.48(s,3H),6.98(d,J=2.5Hz,1H),7.08(d,J=7.5Hz,1H),7.13(d,J=8.0Hz,2H),7.43(d,J=8.0Hz,1H),7.49(d,J=2.0Hz,1H),7.68(d,J=8.5Hz,2H),7.94(s,1H)。13C NMR(CDCl3,125MHz):δ21.47,21.94,102.57,115.60,116.27,116.72,125.32,126.64,129.63,129.65,134.26,134.46,139.65,144.59,144.83,145.84。Product NMR data: 1 H NMR (CDCl 3 , 500MHz): δ 2.27(s, 3H), 2.48(s, 3H), 6.98(d, J=2.5Hz, 1H), 7.08(d, J=7.5Hz) ,1H),7.13(d,J=8.0Hz,2H),7.43(d,J=8.0Hz,1H),7.49(d,J=2.0Hz,1H),7.68(d,J=8.5Hz,2H ), 7.94(s, 1H). 13 C NMR (CDCl 3 , 125MHz): δ 21.47, 21.94, 102.57, 115.60, 116.27, 116.72, 125.32, 126.64, 129.63, 129.65, 134.26, 134.46, 139.65, 144.59, 144.83, 145.
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C18H16NO3S[M+H]+calc.:326.0851;found:326.0855。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C18H16NO3S [ M +H]+calc.: 326.0851 ; found: 326.0855.
实施例4:7-溴-4-Ts呋喃并[3,2-b]吲哚化合物(ID)合成Example 4: Synthesis of 7-bromo-4-Ts furo[3,2-b]indole compound (ID)
在氮气氛围下,向反应管中,加入Ts保护的2-呋喃-4-溴芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(ID),黄色液体,分离收率60%。Under a nitrogen atmosphere, 0.3 mmol of Ts-protected 2-furan-4-bromoarylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, and 0.6 mL of anhydrous copper acetate were added to the reaction tube. mmol, cesium carbonate 0.15mmol. The reaction was carried out at 80° C. for 24 hours. After the reaction was detected by TLC, the reaction was cooled to room temperature to obtain the target product of formula (ID) as a yellow liquid with a separation yield of 60%.
产物核磁数据:1H NMR(CDCl3,500MHz):δ2.31(s,3H),7.00 -7.01(m,1H),7.16(d,J=8.0Hz,2H),7.37-7.39(m,1H),7.55-7.56(m,1H),7.66-7.70(m,3H),7.99(d,J=8.5Hz,1H)。13C NMR(CDCl3,125MHz):δ21.54,102.47,116.68,117.61,119.56,120.14,126.67,126.75,129.81,131.45,134.11,137.77,143.03,145.29,147.26。Product NMR data: 1 H NMR (CDCl 3 , 500MHz): δ2.31(s, 3H), 7.00-7.01(m, 1H), 7.16(d, J=8.0Hz, 2H), 7.37-7.39(m, 1H), 7.55-7.56 (m, 1H), 7.66-7.70 (m, 3H), 7.99 (d, J=8.5Hz, 1H). 13 C NMR (CDCl 3 , 125MHz): δ 21.54, 102.47, 116.68, 117.61, 119.56, 120.14, 126.67, 126.75, 129.81, 131.45, 134.11, 137.77, 143.03, 145.29, 147.26.
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C17H13BrNO3S[M+H]+calc.:389.9800;found:389.9805。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C17H13BrNO3S [ M +H]+calc.: 389.9800 ; found: 389.9805.
实施例5:7-氟-4-Ts呋喃并[3,2-b]吲哚化合物(IE)合成Example 5: Synthesis of 7-fluoro-4-Ts furo[3,2-b]indole compound (IE)
在氮气氛围下,向反应管中,加入Ts保护的2-呋喃-4-氟芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(IE),棕色固体,分离收率67%。MP 114-116℃。Under a nitrogen atmosphere, 0.3 mmol of Ts-protected 2-furan-4-fluoroarylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, and 0.6 mL of anhydrous copper acetate were added to the reaction tube. mmol, cesium carbonate 0.15mmol. The reaction was carried out at 80° C. for 24 hours. After TLC detection was completed, the reaction was cooled to room temperature to obtain the target product of formula (IE) as a brown solid with an isolated yield of 67%. MP 114-116°C.
产物核磁数据:1H NMR(CDCl3,500MHz):δ2.29(s,3H),6.97-7.02(m,2H),7.14(d,J=8.0Hz,2H),7.21(dd,J=8.25,3.0Hz,1H),7.55(d,J=2.0Hz,1H),7.66(d,J=8.5Hz,2H),8.07(dd,J=9.3,4.5Hz,1H)。13C NMR(CDCl3,125MHz):δ21.51,102.60,103.07(d,J=25.9Hz),111.47(d,J=24.9Hz),116.48(d,J=9.6Hz),119.60(d,J=10.9Hz),126.67,129.73,131.94,134.08,135.37,143.85(d,J=2.5Hz),145.16,147.12,159.95(d,J=240.3Hz)。Product NMR data: 1 H NMR (CDCl 3 , 500MHz): δ 2.29 (s, 3H), 6.97-7.02 (m, 2H), 7.14 (d, J=8.0 Hz, 2H), 7.21 (dd, J= 8.25, 3.0Hz, 1H), 7.55 (d, J=2.0Hz, 1H), 7.66 (d, J=8.5Hz, 2H), 8.07 (dd, J=9.3, 4.5Hz, 1H). 13 C NMR (CDCl 3 , 125MHz): δ 21.51, 102.60, 103.07 (d, J=25.9 Hz), 111.47 (d, J=24.9 Hz), 116.48 (d, J=9.6 Hz), 119.60 (d, J= 10.9Hz), 126.67, 129.73, 131.94, 134.08, 135.37, 143.85 (d, J=2.5Hz), 145.16, 147.12, 159.95 (d, J=240.3Hz).
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C17H13FNO3S[M+H]+calc.:330.0600;found:330.0609。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C17H13FNO3S [ M +H]+calc.: 330.0600 ; found: 330.0609.
实施例6:7-甲基-4-Ts呋喃并[3,2-b]吲哚化合物(IF)合成Example 6: 7-Methyl-4-Ts furo[3,2-b]indole compound (IF) synthesis
在氮气氛围下,向反应管中,加入Ts保护的4-甲基-2-呋喃芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(IF),棕色固体,棕色液体,分离收率69%。Under nitrogen atmosphere, into the reaction tube, add 0.3 mmol of Ts-protected 4-methyl-2-furanarylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, and anhydrous copper acetate 0.6 mmol, 0.15 mmol of cesium carbonate. The reaction was carried out at 80° C. for 24 hours. After TLC detection was completed, the reaction was cooled to room temperature to obtain the target product of formula (IF) as a brown solid and a brown liquid, and the isolated yield was 69%.
产物核磁数据:1H NMR(CDCl3,500MHz):δ2.26(s,3H),2.40(s,3H),6.98(d,J=2.0Hz,1H),7.08-7.12(m,3H),7.34(bs,1H),7.51(d,J=2.0Hz,1H),7.65-7.67(m,2H),7.99(d,J=8.5Hz,1H)。13C NMR(CDCl3,125MHz):δ21.30,21.46,102.55,115.09,116.78,119.06,125.26,126.66,129.60,130.36,133.88,134.31,137.48,144.46,144.79,146.25。Product NMR data: 1 H NMR (CDCl 3 , 500MHz): δ2.26(s, 3H), 2.40(s, 3H), 6.98(d, J=2.0Hz, 1H), 7.08-7.12(m, 3H) , 7.34 (bs, 1H), 7.51 (d, J=2.0Hz, 1H), 7.65-7.67 (m, 2H), 7.99 (d, J=8.5Hz, 1H). 13 C NMR (CDCl 3 , 125MHz): δ 21.30, 21.46, 102.55, 115.09, 116.78, 119.06, 125.26, 126.66, 129.60, 130.36, 133.88, 134.31, 137.48, 144.25, 144.79, 146.
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C18H16NO3S[M+H]+calc.:326.0851;found:326.0855。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C18H16NO3S [ M +H] + calc.: 326.0851 ; found: 326.0855.
实施例7:6-Ts苯丙呋喃并[3,2-b]吲哚化合物(IG)合成Example 7: Synthesis of 6-Ts phenylpropylfuro[3,2-b]indole compound (IG)
在氮气氛围下,向反应管中,加入Ts保护的2-苯并呋喃芳胺化合物0.3mmol、N,N-二甲基乙酰胺6mL、二氯化钯0.03mmol、无水醋酸铜0.6mmol、碳酸铯0.15mmol。在80℃反应24小时,TLC检测反应结束后,然后冷却至室温,得到目标产物式(IG),棕色固体,分离收率75%。MP 174-176℃。Under nitrogen atmosphere, into the reaction tube, add 0.3 mmol of Ts-protected 2-benzofuran arylamine compound, 6 mL of N,N-dimethylacetamide, 0.03 mmol of palladium dichloride, 0.6 mmol of anhydrous copper acetate, Cesium carbonate 0.15mmol. The reaction was carried out at 80° C. for 24 hours. After the reaction was detected by TLC, the reaction was cooled to room temperature to obtain the target product of formula (IG) as a brown solid with an isolation yield of 75%. MP 174-176°C.
产物核磁数据:1H NMR(CDCl3,400MHz):δ2.23(s,3H),7.05(d,J=8.0Hz,2H),7.33-7.44(m,4H),7.59-7.61(m,1H),7.64-7.69(m,3H),8.28(d,J=8.0Hz,1H),8.39-8.41(m,1H)。13C NMR(CDCl3,100MHz):δ21.46,112.57,115.77,117.53,118.52,119.24,120.58,123.91,124.39,124.57,124.93,125.39,126.77,129.73,134.20,139.49,144.94,146.67,159.26。Product NMR data: 1 H NMR (CDCl 3 , 400MHz): δ2.23(s, 3H), 7.05(d, J=8.0Hz, 2H), 7.33-7.44(m, 4H), 7.59-7.61(m, 1H), 7.64-7.69 (m, 3H), 8.28 (d, J=8.0Hz, 1H), 8.39-8.41 (m, 1H). 13 C NMR(CDCl 3 ,100MHz):δ21.46,112.57,115.77,117.53,118.52,119.24,120.58,123.91,124.39,124.57,124.93,125.39,126.77,129.73,134.20,139.49,144.94,146.67,159.26。
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C21H16NO3S[M+H]+calc.:362.0851;found:362.0859。High resolution mass spectral data: HRMS (ESI, m/z) calcd. for C21H16NO3S [ M +H] + calc.: 362.0851 ; found: 362.0859.
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements and improvements made within the spirit and principles of the present invention shall be included in the protection of the present invention. within the range.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210469120.0A CN114736212A (en) | 2022-04-29 | 2022-04-29 | A kind of furo[3,2-b]indole derivative and its synthesis method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210469120.0A CN114736212A (en) | 2022-04-29 | 2022-04-29 | A kind of furo[3,2-b]indole derivative and its synthesis method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114736212A true CN114736212A (en) | 2022-07-12 |
Family
ID=82285372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210469120.0A Pending CN114736212A (en) | 2022-04-29 | 2022-04-29 | A kind of furo[3,2-b]indole derivative and its synthesis method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114736212A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115124535A (en) * | 2022-06-16 | 2022-09-30 | 中南民族大学 | A kind of fused ring indole compound and its preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000804A2 (en) * | 2003-06-05 | 2005-01-06 | Merck & Co., Inc. | Substituted indoles and a process for preparing substituted indoles |
CN109096293A (en) * | 2018-08-28 | 2018-12-28 | 中节能万润股份有限公司 | Preparation method of the one kind containing the benzofuran simultaneously alcohol compound of [2,3-b] pyridine structure |
CN110964007A (en) * | 2018-09-30 | 2020-04-07 | 江苏三月光电科技有限公司 | Compound with quinolinone derivative as core and application of compound in organic electroluminescent device |
CN111303171A (en) * | 2020-03-27 | 2020-06-19 | 华中科技大学 | A kind of benzofuranoindole compound, its preparation and application |
-
2022
- 2022-04-29 CN CN202210469120.0A patent/CN114736212A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000804A2 (en) * | 2003-06-05 | 2005-01-06 | Merck & Co., Inc. | Substituted indoles and a process for preparing substituted indoles |
CN109096293A (en) * | 2018-08-28 | 2018-12-28 | 中节能万润股份有限公司 | Preparation method of the one kind containing the benzofuran simultaneously alcohol compound of [2,3-b] pyridine structure |
CN110964007A (en) * | 2018-09-30 | 2020-04-07 | 江苏三月光电科技有限公司 | Compound with quinolinone derivative as core and application of compound in organic electroluminescent device |
CN111303171A (en) * | 2020-03-27 | 2020-06-19 | 华中科技大学 | A kind of benzofuranoindole compound, its preparation and application |
Non-Patent Citations (10)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115124535A (en) * | 2022-06-16 | 2022-09-30 | 中南民族大学 | A kind of fused ring indole compound and its preparation method and application |
CN115124535B (en) * | 2022-06-16 | 2024-02-27 | 中南民族大学 | Condensed ring indole compound and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102311434B (en) | Evodiamine compounds, preparation method thereof and application thereof | |
Cheng et al. | Intramolecular cross dehydrogenative coupling of 4-substituted coumarins: rapid and efficient access to coumestans and indole [3, 2-c] coumarins | |
CN103992336B (en) | Oxa-or thia evodiamine anti-tumor derivant and preparation method thereof | |
CN110437238B (en) | Polycyclic spiroindoline compound and preparation method and application thereof | |
CN107235992B (en) | Indolinone spirotetrahydrothiophene compound and its salt, preparation method and application | |
CN114736212A (en) | A kind of furo[3,2-b]indole derivative and its synthesis method and application | |
CN104744379B (en) | A kind of quianzolinones and its synthetic method | |
Shaikh et al. | Synthesis and biological evaluation of novel carbazole hybrids as promising antimicrobial agents | |
CN114716438B (en) | Derivatives with benzo[7,8]indazine[1,2-c]quinoline skeleton and synthesis method thereof | |
Yan et al. | Catalyst-free synthesis of alkyl 4-oxo-4H-pyrido [1, 2-a] pyrimidine-2-carboxylate derivatives on water | |
Sołoducho | New route to the synthesis of the indolo [7, 6-g] indole (“bis (pyrrolo) naphthalene”) system starting from 1, 5-dihydroxynaphthalene | |
Carullo et al. | Green Synthesis of New Pyrrolo [1, 2‐a] quinoxalines as Antiproliferative Agents in GPER‐expressing Breast Cancer Cells | |
Dong et al. | Short and efficient synthesis of Guillou's Galanthamine intermediate | |
CN108997197B (en) | A kind of cyanocarbazole derivatives and synthetic method thereof | |
CN112979529B (en) | Aromatic amine indole naphthoquinone derivative and preparation method thereof | |
CN101747255B (en) | Isoindolinone compound containing enyne structure and its synthesis method | |
Li et al. | Simple and efficient one-pot multi-step strategy for the synthesis of 2-substituted (1, 2, 5-triarylpyrrolo [3, 2-c] pyridin-3-yl)-N-arylacetamide derivatives in water | |
CN116102552B (en) | Quinoline-2,3-fused nine-membered ring skeleton compound, preparation method and application thereof | |
Surya Prakash Rao et al. | Palladium-catalyzed intramolecular C–N coupling: Facile synthesis of tetracyclic C (3)-aminoisoindolinones | |
Ajay et al. | Rh (III)‐Catalyzed Sequential ortho‐C‐H Bond Annulation and Desulfonylation of 3‐Aryl‐2H‐benzo [e][1, 2, 4] thiadiazine‐1, 1‐dioxides: Access to 1‐Aminoisoquinolines | |
CN109456155A (en) | A method of tetralin ketone derivatives quickly being prepared based on substitution cyclobutanol oxidation open loop/cyclization | |
Bui et al. | Solvent-free strategy for facile synthesis and cytotoxicity evaluation of benzimidazole derivatives | |
CN112300181B (en) | Diketone skeleton compound and preparation method and application thereof | |
CN110105364B (en) | N-p-chlorophenyl substituted maleimide α-terpinene cycloaddition derivatives containing pyrazole structure and preparation method and application thereof | |
CN108997196A (en) | A kind of carbazole analog derivative and its synthetic method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220712 |
|
RJ01 | Rejection of invention patent application after publication |